The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein - fully folded / biologically active in fermentation broth in scale-up studies which can be produced to commercial scale.  This advanced Biomultifold system will be in place and available for future projects to facilitate and bring down costs.  Previously, Paras Biopharma achieved 5-8 g / L in expression levels of a specific therapeutic protein.

Advanced Biomultifold Technology will further facilitate higher expression & production levels for Biologics in critical care / rare disease biologics (manufacturing), thus help to bring down the scale-up biologics production costs / unit.  The company is pleased to bring these developments in ongoing & upcoming projects on biologics and also to share this knowledge for client biologics CDMO work, as needed.